Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey Source: Eur Respir J, 51 (3) 1702571; 10.1183/13993003.02571-2017 Year: 2018
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk Source: Eur Respir J 2012; 39: 1425-1431 Year: 2012
Mycobacterium tuberculosis drug resistance surveillance in BelarusSource: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021
Drug-resistant tuberculosis in Turkmenistan: Results of the first nationwide survey Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
Primary drug resistance against mycobacterium tuberculosis in a high burden country Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
First national survey results of mycobacterium tuberculosis drug resistance in Kosovo, 2007-2008 Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil Source: Eur Respir J , 49 (3) 1602445; DOI: 10.1183/13993003.02445-2016 Year: 2017
Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013
A tale of two settings: The role of the Beijing genotype in the rise of multidrug resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration Source: Eur Respir J 2016; 47: 686-688 Year: 2016
High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public–private initiative Source: Eur Respir J 2012; 40: 1569-1572 Year: 2012
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015
Multidrug resistance of M. tuberculosis and its infuence on treatment efficiency of new detected patients with pulmonary tuberculosis in penitentiary institutions of Belarus Source: Eur Respir J 2007; 30: Suppl. 51, 272s Year: 2007
Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007